Key Summary:
- Renal cell carcinoma brain metastases survival improved versus legacy cohorts.
- Updated Renal GPA stratified median survival from 4.8 to 51.2 months.
- Renal GPA may support treatment individualisation and clinical trial design.

RENAL CELL CARCINOMA brain metastases survival has improved substantially compared with earlier cohorts, while outcomes remain strongly associated with the updated Renal Graded Prognostic Assessment (GPA), according to an international retrospective study of 1,049 patients.
Researchers analysed data from 21 academic institutions involving patients with newly diagnosed renal cell carcinoma with brain metastases treated between January 2016 and December 2022. The cohort was compared with legacy groups treated during 1985–2007 and 2006–2015.
Median overall survival in the contemporary cohort was 20.0 months (95% CI: 18.0–23.4), compared with 9.6 months (95% CI: 8–11) and 12.0 months (95% CI: 5–11) in the respective legacy cohorts.
The contemporary cohort had a median age of 63.9 years, with 773 of 1,049 patients (73.7%) being male. Most patients were White (851; 81.1%).
Lower Karnofsky Performance Status, lower baseline serum albumin, a higher number of brain metastases and extracranial metastases were identified as significant prognostic factors for inferior survival.
Researchers incorporated these factors into an updated Renal GPA to stratify outcomes. Median survival varied substantially across GPA categories, ranging from 4.8 months (95% CI: 3.0–8.1) for GPA 0–1.0 to 51.2 months (95% CI: 34.1–undefined) for GPA 3.5–4.0.
Patients with GPA 1.5–2.0 had a median survival of 12.4 months (95% CI: 10.6–17.2), while those with GPA 2.5–3.0 had a median survival of 33.6 months (95% CI: 27.5–40.0).
Median intracranial progression-free survival was 9.6 months (95% CI: 8.4–10.6). Intracranial progression-free survival also showed a moderately strong correlation with overall survival (Spearman’s rank correlation: 0.74; 95% CI: 0.70–0.78; p<0.0001).
The findings suggest that the updated Renal GPA could help clinicians estimate prognosis across a broad range of outcomes in patients with renal cell carcinoma brain metastases. The assessment may also support treatment individualisation and provide a framework for clinical trial design and stratification.
The authors concluded that survival had improved compared with legacy cohorts but continued to vary widely according to GPA. The updated assessment could also help refine clinical trial eligibility and estimate both overall and intracranial progression-free survival.
Reference
Sperduto PW et al. Survival in patients with renal cell carcinoma and brain metastases: an update of the Renal Graded Prognostic Assessment. Lancet Oncol. 2026;DOI: 10.1016/S1470-2045(26)00385-2.
Featured image: crizzystudio on Adobe Stock
Each article is made available under the terms of the Creative Commons Attribution-Non Commercial 4.0 License.